As its contract with the National Cancer Institute nears completion, startup Mirimus is hoping to begin adding drug companies to the list of customers for its inducible-RNAi mouse models, Mirimus CEO Prem Premsrirut said this week.

At this point, the majority of Mirimus' clients are academics, which have been easier to approach given Mirimus' status as a spinout of Cold Spring Harbor Laboratory, she told Gene Silencing News. “The commercial customers we're aiming for ... will take a little bit more time.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.